NCT00590122: Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study |
|
|
| Completed | 4 | 20 | US | Parcopa, carbidopa-levodopa (Sinemet) | Baylor College of Medicine, UCB Pharma | Parkinson's Disease | 10/08 | 11/08 | | |
2009-017416-33: Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol. |
|
|
| Completed | 4 | 24 | Europe | Tolcapon, Entacapon, Levodopa/Carbidopa, TO, EN, LD/CD, Coated tablet, Tasmar, Comtess, Isicom | Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University | Male and female patients with Parkinson´s disease meeting UKPDS criteria | | | | |
2008-006278-13: Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations. |
|
|
| Ongoing | 4 | 10 | Europe | Reminyl Retard, Sinemet 125 mg, Reminyl Retard, Sinemet 125 mg | UMCG | patients with advanced (>5 years) Parkinson\'s disease and visual hallucinations. | | | | |
2013-004229-10: Placebo effect in Parkinson\'s disease El efecto placebo en la enfermedad de Parkinson |
|
|
| Ongoing | 4 | 60 | Europe | Sinemet 25/250, Sinemet 25/250 | Raul de la Fuente-Fernandez, Complejo Hospitalario Universitario de Ferrol (CHUF) | Parkinson\'s disease Enfermedad de Parkinson | | | | |
